Seven anonymised accounts of real early-stage university R&D and IP projects. What we were working with, where it got hard, what we learned and how each one changed the way PIPE works.
Every project we take on teaches us something. Some lessons confirm what we suspected. Others only emerge after months of careful work, difficult conversations and the occasional dead end. The accounts below are drawn from real projects, anonymised and condensed.
They are an honest record of what we have learned about moving early-stage university R&D and IP from the bench towards commercial reality.
A research team at a British university had developed a novel thermochemical energy storage device: in effect, a high-density thermal battery charged using existing electric vehicle infrastructure. Rather than storing energy as electricity, the system stores it as heat and cold via a reversible chemisorption process, then uses it to manage cabin temperature and thermal loads independently of the primary battery pack. The claimed benefit was an improvement in EV driving range of up to 70%, alongside extended battery lifespan and reduced HVAC energy draw. The IP was protected by patent application and the academic team were enthusiastic and well published in the field.
The project arrived with genuinely exciting science and a compelling headline number. Translating that number into a credible commercial proposition proved considerably harder than it first appeared. The primary difficulty was market positioning. The device could, in principle, serve EV range extension, domestic heating, industrial thermal management and grid-adjacent storage. Trying to address all of these simultaneously is a classic early-stage trap. Each market has fundamentally different customers, routes to adoption, regulatory requirements and competitive dynamics. Without a clear first beachhead, the proposition risked being everything to everyone and nothing to anyone.
The academic framing, necessarily broad and exploratory, had to be translated into a specific, credible commercial narrative that an investor or industry partner could act upon. The existing EV infrastructure compatibility, whilst a genuine advantage in principle, also needed validation against real OEM requirements. What works in a university laboratory does not automatically integrate into a production vehicle programme.
This project made clear that no matter how robust the commercialisation process, it cannot substitute for direct industry engagement. The technology required a corporate partner with genuine OEM knowledge to assess whether the integration case was real, and to provide the credibility with investors that an academic team alone cannot supply.
The experience directly informed our decision to develop a formal corporate partnering programme, giving projects access to industry expertise before significant capital is committed, not after.
A university researcher had developed a novel integrated circuit design for reading the quantum state of silicon qubits: a critical but poorly solved problem in the race to build scalable quantum computers. The invention used a capacitance-based detection principle implemented in standard silicon CMOS, the same manufacturing process used for conventional microprocessors. Rather than requiring exotic materials or off-chip analogue components, the readout circuit could, in principle, be fabricated in any existing silicon foundry. The readout circuitry was roughly 100 times smaller per qubit than the dominant LC resonator approach and consumed as little as 61 microwatts at operating frequency, a critical constraint because quantum processors operate at temperatures close to absolute zero.
The researcher's stated commercial vision was modelled on ARM Holdings: build a library of licensable IC designs rather than manufacturing chips directly, and license the IP to quantum hardware developers worldwide.
This was one of the most technically sophisticated and commercially complex projects we have engaged with. The quantum computing sector was, as one correspondent put it, very fluid. Multiple competing hardware approaches were in play and no dominant architecture had emerged. The ARM licensing model was intellectually compelling but required a library of IP, not a single patent. Building that library required further prototyping, further research and further investment. The first milestone alone, prototyping the readout IC, was estimated at approximately £200,000 and twelve months of effort before any commercial validation.
Finding the right associate proved harder than anticipated. The profile required was unusual: deep CMOS and IC commercialisation experience, a working understanding of how an ARM-style licensing model operates in practice, and sufficient familiarity with the evolving quantum computing market to sell a long-horizon proposition. People who combine all three are rare. The researcher's preference for remaining in academia added a further layer of complexity. This is entirely understandable but has significant implications for the structure of any resulting venture and the profile of the leadership team that needs to be built around the IP.
The project made clear that certain categories of deep tech require a form of patient, staged capital that conventional funding rounds are poorly structured to provide. Pre-seed and seed rounds are designed around milestones that assume a degree of commercial readiness this project did not yet have. What was needed was proof of concept funding, disbursed carefully and tied directly to technical milestones, with no expectation of near-term revenue.
The experience shaped our thinking about how the PIPE Associate Network should work and what kinds of capital structures are needed to support very early-stage deep tech. Not every project fits a conventional funding ladder, and the infrastructure we have built since reflects that.
A university research team had developed a novel unsupervised detection system for identifying advanced persistent threats hidden within the normal network traffic of enterprise applications. The system, built on a combination of Continuous Time Hidden Markov Models and Time Series Decomposition, was designed to detect beaconing: the regular, low-frequency communications that compromised machines send back to attacker-controlled servers. This behaviour is a hallmark of sophisticated malware and notoriously difficult to detect because attackers deliberately disguise it as ordinary application traffic. The key innovation was operating without labelled training data, meaning it could identify novel threats that no existing signature database had catalogued.
The technology was strong and the problem it solved was real. Beaconing-based attacks are responsible for some of the most damaging breaches in recent years, and existing tools generate high volumes of false positives that exhaust security operations teams. The challenge was one of commercialisation framing, not scientific validity. The cybersecurity market is crowded and fast moving. Enterprise buyers are sceptical of academic research that has not been hardened into production-grade software, and the gap between validated on benchmark datasets and deployable in a live enterprise environment is substantial. The team had not yet mapped a credible path across it.
Operating without labelled data was a genuine differentiator but made the proposition harder to explain to non-technical buyers. Route to market was also unresolved. Selling directly to enterprise security teams requires significant sales infrastructure and credibility that an academic team does not have. The more natural route, integration with an existing security platform, required partnership conversations the team was not yet positioned to have.
This project reinforced something we had been learning across multiple engagements: the research team and their institution needed a clear, structured output that told them honestly where they stood, what was missing, and what needed to happen next. The report they received had to be evidenced and actionable, not simply a list of concerns. It also had to be written in a way that supported them in moving forward rather than simply closing the door.
Working through this project contributed directly to the development of the Disclosure and Validation Report as a standard output for all projects we assess. It is a repeatable, structured framework that gives every research team a clear Go, No Go or Rework verdict alongside a specific set of actions, written in language that encourages progress rather than discourages it.
A university team had developed a compact, portable device designed to objectively measure the hand tapping test used in clinical assessment of Parkinson's disease. The device records tap count, inter-tap intervals and dwell time during a standard thirty-second test, feeding the data into a custom software platform for analysis and transfer to clinicians, enabling remote and continuous monitoring between appointments. Parkinson's disease has over forty associated symptoms, many of which fluctuate significantly across a single day and in response to medication. Existing assessment relies on infrequent in-person appointments that capture only a snapshot and are subject to examiner variability.
The technology was well conceived and the clinical rationale was sound. The challenge was not whether the device was useful. It was how to get it into clinical practice. The NHS adoption pathway for MedTech is long, structured and resource intensive. A device at the boundary between consumer health technology and regulated medical device faces a particularly complex journey. Depending on classification, the regulatory burden under UKCA and EU MDR can be substantial, requiring clinical validation, quality management systems and technical file documentation that early-stage academic teams are rarely equipped to produce alone.
Reimbursement was a further consideration the team had not fully addressed. A device is only commercially viable if someone will pay for it, and in the NHS context that requires demonstrating health economic value as well as clinical utility.
Working with this project made it clear that the standard PIPE QED framework, whilst effective across a wide range of sectors, needed to be extended for MedTech. The regulatory journey in healthcare does not map neatly onto a generic technology readiness ladder. Specific regulatory milestones, governance requirements and customer discovery processes needed to be embedded into the workflow, not bolted on afterwards.
We subsequently developed additional structured streams within the QED framework to handle sectors with their own mandatory processes, including Legal, Governance and Risk, and Customer Discovery. The system is now designed so that a research group with a sector-specific requirement can have a tailored workflow built into their instance of the process, maintaining the rigour and decision-making integrity of the overall framework whilst reflecting the real demands of their particular context.
A research team had developed an AI-driven framework for recovering critical materials from end-of-life solar panels and equipment. The problem was real and urgent. The global installed base of solar photovoltaic panels is ageing rapidly, and the materials within them, including silver, indium, tellurium and high-purity silicon, are both strategically valuable and increasingly difficult to source. Existing recycling processes recover relatively little of this value. The team's approach used AI to optimise material recovery workflows, with complementary research into photonic crystal solar cell architectures and solid-state lithium-ion battery anodes using recycled silicon.
The technology portfolio was broad and genuinely innovative, but it comprised several distinct commercial opportunities bundled into a single proposition. AI-driven recycling, novel solar cell architecture and solid-state battery anodes each represent a different technology, a different market and a different competitive and regulatory landscape. Attempting to commercialise all three simultaneously made it impossible to present a clear, compelling investment case.
The AI component added both value and complexity. Optimising a physical recycling process with AI requires substantial process data that can only be generated at scale, creating a situation where the AI is most valuable once you have volume but you need the AI to make the economics work at volume. This data dependency needed to be addressed in the commercialisation plan, not left as an assumption. With multiple technology threads, each potentially patentable and each with different licensing or spinout implications, the IP structure also needed careful attention.
This project was one that would have benefited from early, informal exposure to industry experts and potential investors before it entered the formal Disclosure and Validation stage. The proposition was complex enough that a structured pre-disclosure conversation, with people who understood both the materials science and the commercial landscape, would have significantly sharpened the focus before substantive resource was committed.
The experience contributed directly to our thinking about what is now Stage 0 of the Lab to IPO Pathway: an informal mechanism for testing ideas at a high level with relevant experts before full disclosure. The intent is to surface the hard questions early, provide a first read on viability from people with direct sector knowledge, and give research teams a clearer sense of where to focus before the formal process begins. It is not a gate. It is a conversation.
A multidisciplinary university team, combining analytical chemists, chemometricians and clinicians, had developed a methodology applying metabolomics to the perioperative investigation of complex congenital heart disease, with a particular focus on Fontan disease. Metabolomics involves the systematic analysis of small molecules in biological samples. The team's work aimed to unlock metabolic pathway information that could enable earlier medical intervention, better monitoring and improved management of a condition that is both complex and life limiting. A key innovation was the use of commercially available blood micro-sampling devices, dramatically reducing patient burden compared with conventional blood collection. This was particularly significant for paediatric patients and for patients in rural or under-resourced settings where standard collection by trained phlebotomists is difficult.
This was one of the most genuinely affecting projects we have worked with. The clinical need is profound, the patient population is vulnerable, and the team's commitment to patient experience showed a rare alignment between scientific innovation and human-centred design. The commercialisation challenges were substantial but of a different character to most projects we encounter. The primary difficulty was not market definition or competitive positioning. The combination of metabolomics, micro-sampling and Fontan disease is a relatively uncrowded space. The challenge was the regulatory and clinical validation pathway, which for a diagnostic or monitoring tool used in the perioperative care of children with complex congenital heart disease is necessarily demanding.
Translating a metabolomics-based approach into a validated, reimbursable clinical product requires a significant body of prospective clinical evidence, a process that takes years and considerable funding. The dual application across paediatric specialist care and rural point-of-care monitoring, whilst both compelling, implied different customers, different regulatory classifications and different reimbursement pathways.
Projects of this kind, focused on conditions that disproportionately affect patients in under-resourced settings or in the Global South, sit in a difficult position within conventional investment markets. Many investors, even those with genuine interest in impact, are not structured to engage with what is essentially a health system proposition in low- and middle-income contexts. The capital requirements, timelines and revenue models do not fit the standard playbook.
This project was one of several that made clear we needed access to a broader and more diverse range of capital than conventional venture funding provides, including mechanisms for smaller investors and those from the regions the technology is designed to serve. The funding infrastructure we have built since reflects that need.
A university research team had developed a biological methanation process capable of converting carbon dioxide and green hydrogen into synthetic methane using a microbial catalyst. The process is anaerobic and operates via a biochemical reaction in which microorganisms consume CO₂ and H₂ and produce CH₄, at conversion efficiencies the team had measured at approximately 98% under laboratory conditions. The technology had been evaluated across multiple reactor configurations at laboratory scale, including oscillatory baffled reactors, tubular baffle reactors, continuously stirred tank reactors and recirculating column reactors. Work had been part-funded by Innovate UK, BBSRC and BEIS, and the project had been progressed through the full PIPE QED framework, generating over seventy structured deliverables spanning market validation, partner identification, pilot definition, IP allocation and commercial roadmap.
The project arrived with a genuine head of steam. The science was well validated, the funding pedigree was credible, and the team had been thorough in their technical documentation. Yet despite this productivity, the fundamental commercial questions remained genuinely open. The team could articulate what the process did with considerable precision. Who would pay for it, on what terms and via what commercial structure was harder to answer. Green gas and carbon utilisation markets were evolving rapidly, with the regulatory and subsidy landscape shifting in ways that made longer-term revenue projections difficult to anchor. Gas grid injection in the UK is a particularly demanding route to market and, at the point of engagement, those regulations were themselves in flux regarding hydrogen blend tolerances.
The breadth of potential feedstock and application scenarios compounded the difficulty. The process could operate on CO₂ from anaerobic digestion, from industrial point sources, or from concentrated atmospheric capture systems. Each route implied a different customer, a different regulatory framework and a different commercial partnership structure. Role coverage was a further issue. Key positions including the lead academic, business associate and several client-facing roles were either unassigned or flagged as outstanding throughout much of the project period.
The team had represented the project as being at TRL 6 on entry. We challenged that assessment and, after discussion, agreed on TRL 4 to 5. However, once the formal disclosure process began and we undertook our standard audit, working back through each stage from TRL 1, it became clear the project should have been assessed at TRL 2. More significantly, the underlying commercial premise assumed the cost of raw materials that did not hold. Once that assumption was corrected, the project as structured was not commercially viable. The university and UKRI had invested a substantial sum on the basis of the original assessment, and our findings were not well received. We were subsequently encouraged to produce a report that would support the next tranche of public funding rather than reflect our actual conclusions.
We declined to do so. External, independent commercial review should happen before public funds are committed, not after. Universities and their technology transfer teams should be willing to trust the findings of external partners even when those findings are uncomfortable. And both academics and institutions need to understand that commercialisation is not something that happens alongside research. It requires its own structure, its own people and its own processes, and that support is most effective when it comes from partners whose only interest is in getting the outcome right.
The PIPE framework was not designed in a meeting room. It was built project by project, from the questions that were not answered and the gaps that commercial reality exposed. Every feature below exists because a real project revealed that it was needed.
The Quantify, Evaluate, Deploy framework applies structured Go / No Go assessment across commercial, environmental and societal dimensions before any resource is committed. Sector-specific streams for MedTech, Legal and Governance, and Customer Discovery were built directly from project experience and embedded into the framework, not bolted on afterwards.
Explore QED →Born from projects that arrived at the formal process carrying assumptions that should have been tested earlier, Stage 0 is an informal mechanism for surfacing hard questions at a high level with relevant experts before full IP disclosure. It is not a gate. It is a conversation. One paragraph, fingerprinted, community reviewed, and no inventive step required.
Post a Napkin Idea →Every research team receives a repeatable, evidenced framework giving a clear Go, No Go or Rework verdict alongside specific, actionable next steps written in language that encourages progress rather than discourages it. The structure of this report was developed through projects that needed honest assessment without a closed door.
Submit an innovation →Projects like the quantum computing story made clear that finding the right associate is as important as the IP itself. Someone with deep domain knowledge, commercial model understanding and the willingness to work within a structured ecosystem rather than ad-hoc advisory. The PIPE Associate Network provides curated access to experienced operators who are embedded into projects from the point where they can add most value, shaping ventures and sharing in the upside through milestone-aligned economic participation. Associates build a portfolio of translational value creation across disciplines and stages, from TRL 3 through to PIPExchange listing.
Join the Associate Network →The quantum and life sciences projects made clear that conventional funding rounds, designed around milestones that assume a degree of commercial readiness many early-stage projects do not yet have, are the wrong instrument. The PIPE Investor Network provides structured access to patient, aligned capital disbursed carefully and tied directly to technical milestones. Investors gain access to opportunities that have been curated, TRL validated, commercially structured and Associate-embedded before capital is deployed. The network is designed to accommodate a range of investor types, including those motivated by impact alongside return, and those from the regions the technology is designed to serve.
Join the Investor Network →The experience of projects that reached commercial readiness without a clear mechanism for connecting validated IP with the right capital directly informed the development of PIPExchange. Projects that successfully complete the PIPE incubation pathway can be listed on the PIPExchange, securing future funding rounds with no upper limit, all the way through to full IPO. The exchange ensures that validated, investor-ready opportunities are visible to a curated network of aligned investors who understand what early-stage science-backed IP looks like and are prepared to engage with it at the right stage.
Explore PIPExchange →The life sciences and green gas projects, among others, surfaced a consistent problem: the funding and governance structures that conventional markets offer are poorly matched to the timelines, risk profiles and multi-stakeholder realities of frontier research commercialisation. The PIPE gDAO provides on-chain governance that gives researchers, universities, associates and investors a transparent seat at the table, with fair economic participation from day one. Up to €2m in initial funding is available through the PGF Launchpad, structured against KPI-gated tranches, with no upper limit on subsequent rounds as projects progress to PIPExchange listing.
Explore the PIPE gDAO →All projects described above have been anonymised. Names of researchers, institutions and commercial partners have been removed or generalised. labtoipo.info · The PIPE Company OÜ (UK) Limited · 2026
Whether you have a fully formed innovation or just a napkin sketch, there is a place on the PIPE pathway for where you are right now.